19 December 2023
19 December 2023
Our most popular stories of the year involve CRISPR therapies, generative AI, obesity drugs entering prime time, and changes in the Covid-19 landscape, signaling the biggest trends in the pharmaceutical and biotech industry.
Illumina aims to finalise the terms of this divestiture by the end of the second quarter of 2024.
Keytruda plus gemcitabine and cisplatin is intended for use as a first-line therapy to treat adult patients.
Following US and UK approvals, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Casgevy, with a decision expected in Q1 2024.
Lilly will receive $50m in upfront payment and milestone payments based on product sales.
The latest $389m pledge follows an initial investment of $300m in 2017 that was raised to fund early-stage life-science startups.
The companies will prioritise challenging drug targets across multiple therapy areas, leveraging Anagenex’s AI platform.
The foundation has invested Dkr1.8bn in the initiative to develop vaccines for tuberculosis, influenza, and group A streptococcus.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.
